Is ATAI Live Sciences (ATAI) $2.00, Finally Turning?
After dropping 94% from post IPO high from $19.45, a loss exceeding $3 billion and change, ATAI is in the early stages of recovery (in...
The Ketamine Endgame. Silo Pharmaceutical (SILO).
James Kuo, M.D. the Vice President of R&D for Silo Pharma (SILO) will speak at the 3rd...
The Ketamine Cure (NY Times)
The once-taboo drug has been repurposed to treat depression and is even available for delivery. But how safe is it?
A Good Bear Market, is a Terrible Thing to Waste. How to Short Real...
"The commercial real estate market is tumbling toward a crash that could be as devastating as the 2008-09 crisis. The party’s over,...
The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s Novel Topical Ketamine Delivery.
Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted to Relieve PTSD Symptoms Within Minutes and Negate Side Effects
Ardelyx (ARDX) Resubmits New Drug Application to FDA.
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
Psycheceutical Bioscience Inc.’s (BWVI) Novel Topical Ketamine Delivery.
Rick Doblin, Recently Visited one of Psycheceutical's Labs.
Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted...
And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.
LIVE QUOTE
Longer Term Chart
Ardelyx Enters the Danger Zone* With Tenapanor.
Maxim Group Targets 175% Gain in Society Pass (SOPA) to $2.75.
If we average out the two most recent price targets this month, we come out with a potential gain of 337% and...
Updating Coverage Report: Two Binary Events Rapidly Approaching Principal Solar (PSWW).
Electric Vehicle EV Engine ‘Retro-Fitting’ Company Nearing Commercialization
Minerva Oil Field Deal Valued at $116 Million, Nearing...